AQP1 and Pleural effusion: Furthermore, treatment of noncycling PMSG-/hCG-induced OHSS rats (to exclude any cyclic influence) with 300 μl CFTR antiserum (1:100 dilution, vol/vol, in buffer; Zymed Laboratories) or 400μl AQP1 antiserum (1:100 dilution, vol/vol, in buffer; Santa Cruz Biotechnology) by IP injection to suppress the function of CFTR or AQP1 resulted in the elimination of body WT increase, ascites volumes and pleural effusion volumes (Figure 6 D-F).